Chairman

Dr. Oster has more than 25 years of experience in the healthcare sector. He started his career in academic medicine, trained in Europe and the U.S., received board certifications for internal medicine, hematology, and oncology, and served as adjunct Professor at the Brown Medical School as well as at the University of Freiburg, Germany. He is the author of more than 100 publications and a recipient of the Johann Georg Zimmermann Award for Cancer Research.

Dr. Oster crossed over to industry at Behringwerke (a former Hoechst subsidiary) where he led global clinical programs. Subsequently he held Senior Executive positions at U.S. Bioscience, Medimmune and NeoRx before he joined PolyTechnos Venture Partners as Managing Partner in 2002. During his tenure as Executive, Board Member and Investor he oversaw multiple developments of drugs, diagnostics and medical devices from earliest stages to market introduction in all relevant worldwide markets. He was involved in some of the most prominent developments and approvals over the past two decades, including hematopoietic growth factors, cytokines, monoclonal antibodies, cytotoxic and cytoprotective agents, methylation-based technologies for diagnostic purposes, interventional technologies in neurology and cardiology etc. At PolyTechnos he built a life science portfolio leading to multiple U.S. and European IPOs, including Devgen, Jerini, Addex, OMS, and Micrus, as well as trade sales, including BiPar, Jerini and Micrus.

Dr. Martin Stogniew

Dr. Stogniew brings 29 years of senior executive experience in the pharmaceutical industry. He has been responsible for all areas of domestic and international drug development, including proprietary, generic, and over the counter drugs, as well as nutritional supplements. He has made significant contributions resulting in FDA approval of eight New Drug Applications, issuance of twenty-six US patents, and closure of three major M&A deals. In 2008, he founded a company providing high level consulting to the pharmaceutical industry.

Currently, Dr. Stogniew holds the position as Chief Technology Officer at Yaupon Therapeutics. Formerly, he was Executive Vice President, Chief Technology Officer of Prestwick Pharmaceuticals and was accountable for all technical and regulatory diligence during the sale of the company to Biovail for $150M. Prior to this role, he was Executive Vice President of Development and Corporate Officer for Zelos Therapeutics. Previously he was Executive Vice President, Scientific Affairs and Executive Officer for Vicuron Pharmaceuticals where he played an integral part in the sale to Pfizer for $1.9B. Dr. Stogniew was responsible for regulatory affairs, intellectual property, non-clinical, CMC, Phase 1, and drug supply manufacturing. He was Vice President, Pharmaceutical Sciences and Corporate Officer for US Bioscience, which he helped sell for $492M. He completed a post doctoral fellowship at The Johns Hopkins University, School of Medicine, earned a PhD in Medicinal Chemistry from the University of Maryland and received a BS in Pharmacy with honors from the University of Maryland.

Dr. A. Wayne Tamarelli

Dr. Tamarelli has 39 years experience in general management, entrepreneurship, new ventures, mergers and acquisitions, advanced materials, environmental protection products, energy conservation technologies, specialty chemicals, technology transfer, and other business and technological areas. His primary business activity is as a professional venture capital angel investor. He specializes in value-added investments in early stage technology businesses. He has made about 70 investments in over 30 companies since 2000. These investments have been in advanced materials, electronics, information technology, and health care. He is also a limited partner in 4 venture capital funds active in these areas. Dr. Tamarelli is founding chairman of Jumpstart New Jersey Angel Network and a member of the Band of Angels in Silicon Valley. In 1983 he purchased Dock Resins Corporation in a leveraged buyout and successfully grew its revenues and profits as Chairman, CEO and sole owner. In 1997 he sold the company at a significant gain and remained CEO until 2000 when he became Chairman Emeritus. He was employed by Engelhard Corporation from 1970 to 1983 (Senior Vice President), and previously by Exxon Corporation. He has BS, MS, and PhD degrees in engineering from Carnegie-Mellon University and an MBA in marketing and international business from New York University.

Bryan Wood

Mr. Wood is the founder of Alta Berkeley, a European venture capital firm investing in early stage communications, information technology, media and health care companies in Western Europe, USA and Israel. He has invested in 40 companies, resulting in nine IPOs (six on NASDAQ) and fourteen trade sales (mostly cross-border). He served as non executive director of 50 companies, public and private in ten European countries, USA and Israel.

Previously, Mr. Wood has been European Finance Vice President of Gould Inc and held several other European and US finance and operating positions in various companies. Bryan obtained his Bachelor in Science in Industrial Engineering from the Virginia Polytechnic Institute and his MBA from the Harvard Business School.

CEO/CSO

Dr. Olson is co-founder, President & CEO of Provid Pharmaceuticals. He received an A.B. from Columbia and his Ph.D. in chemistry from Stanford. He is a leading expert in medicinal chemistry and a pioneer in the fields of drug design and peptide mimetics. Dr. Olson was a research scientist at Hoffmann-La Roche for 26 years where he became Research Director in the Departments of Inflammation/Autoimmune disease and Oncology. In 1998, he joined Praecis Pharmaceuticals as Senior Vice President of Chemistry R&D. He co-founded Provid in 2001 and has led the company's drug discovery services business and internal programs in autoimmune disease and oncology therapeutics. He is also an adjunct Professor of Medicinal Chemistry at Rutgers.

VP Medicinal Chemistry

Dr. Self has broad experience in the pharmaceutical industry and expertise in organic and medicinal chemistry applied in the fields of inflammation, autoimmune diseases, and oncology. He received a B.Sc. in chemistry from Imperial College, London in 1977, and his Ph.D. at the University of London under the direction of Prof. Stephen Ley. Following a postdoctoral appointment at Wisconsin with Prof. Barry Trost, he joined Roche Products Ltd., UK, in 1982 as a senior researcher in the Department of Inflammation, and from 1995 held the position of Research Leader at Hoffmann-La Roche Inc., USA in the Department of Inflammation/Autoimmune Diseases. In 1998, Dr. Self became Vice President, Medicinal Chemistry of Praecis' New Jersey division, and became a co-founder of Provid in 2001 where he is currently Vice President of Medicinal Chemistry.

CFO

Mr. Thomas is a biotechnology executive and entrepreneur, having been a founder, advisor, and principal in a number of successful life science companies. Prior to joining Provid, Mr. Thomas occupied executive positions with CMI - Centers for Medical Innovation AG (antivirals, Munich and Princeton), Precision Pharmaceuticals Inc. (anti-inflammatories, Gainesville, FL), and Avid Therapeutics (antiviral drug discovery, Philadelphia). He is also a founder and CEO of Eleison Pharmaceuticals. Mr. Thomas was educated at the University of Pennsylvania (B.S., Economics and Biochemistry, 1981) and earned an MBA from The Wharton School in 1984.